Study: New drug prevents cytomegalovirus in stem cell transplant patients

09/25/2013 | Medscape (free registration)

A new oral antiviral drug that contains cidofovir proved effective in preventing cytomegalovirus infection in patients who had allogeneic hematopoietic cell transplants. A Phase II study published in the New England Journal of Medicine found that 10% of patients treated with CMX001 reported CMV incidence, compared with 37% in a placebo group.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Associate General Counsel Business Law
Takeda Pharmaceuticals
Cambridge, MA